Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07011342 · ClinicalTrials.gov registry record · NA
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
A NA study of Prostate Cancer, sponsored by Hackensack Meridian Health.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT07011342 is a NA study of Prostate Cancer that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 70 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07011342, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by Hackensack Meridian Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the effectiveness of a PSMA-PET scan in identifying recurrent prostate cancer after focal therapy
Conditions Studied
Interventions
- DRUG 18F-rhPSMA-7.3
Study Locations (1)
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2028-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07011342
The ClinicalTrials.gov registry entry for NCT07011342 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which 18F-rhPSMA-7.3 is the first listed.
NCT07011342 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT07011342 about?
NCT07011342 is a clinical study titled "Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment". To evaluate the effectiveness of a PSMA-PET scan in identifying recurrent prostate cancer after focal therapy
What is the current status of trial NCT07011342?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-10-01. Estimated completion is 2028-11.
What conditions does trial NCT07011342 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT07011342?
The interventions under investigation include: 18F-rhPSMA-7.3 (DRUG).
Who is sponsoring clinical trial NCT07011342?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07011342 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.